Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Biotechnology

Healthcare
$10.19 -1.58%

-$0.19 today

Market cap
$859.56M
Beta
0.84
P/E (TTM)
-24.1
EPS (TTM)
-$0.49
52W Low $3.55High $26.95

Volume 0.99M

Average 1.49M

CRVS Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Corvus Pharmaceuticals, Inc.NASDAQ: CRVS

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash turns positive

Q1 FY2026 net change in cash was $35.53M, compared with -$3.74M a year earlier. Trailing-twelve-month net change in cash was $35.1M. Over 3 fiscal years it compounded at -56.4% a year.

Context

  • Net change in cash grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly net change in cash holds near $35.53M or moves back toward the trailing-twelve-month quarterly average of $8.78M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$35.53M+1978.8% QoQ
Last fiscal yearDec 2025
-$4.16M+7.3% YoY
LTMMar 2026
$35.1M+1528.7% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1049.6%——
1 year+7.3%——
3-year CAGR-56.4%——
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(4.16M) USD
Year-over-year change
-7.3%

Net Change in Cash vs competitors

How CRVS compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1528.7% is the highest of 8, against a peer median of -18.7%.
  • Over three fiscal years its annual growth of -56.4% compares with a peer median of +11.7%.
CRVS Competitors
Net Change in Cash for CRVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ADAGAdagene Inc.LTM Jun 2024$161.85M USD—-29.6%19840.3%
RCUSArcus Biosciences, Inc.LTM Jun 2026$98M USD-206.5%+7.5%83.8%
MGNXMacroGenics, Inc.LTM Mar 2026$79.05M USD-221.2%+105.0%50.3%
CGENCompugen Ltd.LTM Dec 2025$72.37M USD—+192.0%99.5%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$35.1M USD+1528.7%-56.4%—
CHRSCoherus Oncology, Inc.LTM Mar 2026$32.8M USD+118.5%-52.8%70.0%
IPHAInnate Pharma S.A.FY2025€30.44M EUR+623.1%+15.9%1092.1%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$18.28M USD-258.5%+28.0%51.4%
NKTRNektar TherapeuticsLTM Jun 2026$15.21M USD+1.2%—27.9%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$14.12M USD-18.7%-51.1%—
Peer median (excluding CRVS) —-18.7%+11.7%76.9%

Competitors are the stored peer set for CRVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(43.24M)(41.31M)(27.03M)(62.29M)(15.28M)
Depreciation & Amortization460K367K151K85K105K
Deferred Income Tax00000
Stock-Based Compensation4.23M2.69M2.15M3M5.33M
Change in Working Capital(3.24M)1.41M(3.59M)(1.65M)3.58M
Accounts Receivables(507K)(81K)562K(49K)38K
Inventory00000
Accounts Payables(1.9M)411K(451K)1.06M(91K)
Other Working Capital(827K)1.08M(3.71M)(2.66M)3.63M
Other Non-Cash Items5.07M9.81M4.39M35.43M(26.53M)
Operating Cash Flow(36.72M)(27.02M)(23.94M)(25.42M)(32.8M)
Capital Expenditures(5K)(269K)(34K)0(174K)
Acquisitions (Net)(21.57K)22K05K0
Purchases of Investments(9.36M)(66.19M)(47.05M)(70.12M)(91.75M)
Sales of Investments30.92M43.16M62.62M42.63M84.13M
Other Investing Activities21.57K0000
Investing Cash Flow21.56M(23.28M)15.54M(27.48M)(7.8M)
Debt Repayment00000
Common Stock Issued60.94M07.84M16.41M36.43M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.22M012K32.62M0
Financing Cash Flow62.16M07.86M49.03M36.43M
Effect of Forex Changes00000
Net Change in Cash47M(50.3M)(539K)(3.88M)(4.16M)
Free Cash Flow(36.72M)(27.29M)(23.97M)(25.42M)(32.97M)

Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Intrinsic Alpha fair value

Locked

Current Price

$10.19

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.